NCT04141592
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Jul 31, 2026 to Jul 31, 2027
- Eligibility criteria expanded, about 12 words
- Collaborators: details revised at 2 of 3 entries
- Minor Primary and study completion dates: Apr 1, 2026 to Jul 31, 2026v6
- Notable Primary and study completion dates: Apr 1, 2025 to Apr 1, 2026v5
- Notable Primary and study completion dates pushed to Apr 1, 2025
- Start date: Feb 19, 2019 to Mar 5, 2019
- Notable Primary completion date: Feb 5, 2023 to Sep 5, 2023
- Study completion date: Sep 5, 2023 to Dec 29, 2023
- Study arms: 4 to 3
- Notable Primary completion date: Sep 5, 2020 to Feb 5, 2023
- Study completion date: Sep 5, 2020 to Sep 5, 2023
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Impact of weight loss surgery upon Non-alcoholic steatohepatitis
Timeframe: Two years
Secondary (1)
Impact of weight loss surgery upon Non-invasive measures of fibrosis
Arms and interventions
Healthy Control
non-obese individuals without fatty liver disease
Obese wihtout non-alcoholic steatohepatitis
Body mass index greater than 30 without liver histological evidence of non-alcoholic fatty liver disease
Obese Non-alcoholic steatohepatitis
Body mass index greater than 30 with liver histological evidence of non-alcoholic fatty liver disease
Procedures: Bariatric Surgery
Sites
1 site in 1 country
- Homerton University Hospital Foundation TrustLondon, Greater London, United Kingdom